{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-23-000871","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2023-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.103423+00:00","generated_at":"2026-06-20T12:33:15.304554+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Alzamend Neuro updates corporate presentation; no material new details disclosed","bullets":["Alzamend Neuro refreshed its investor presentation for meetings with investors and analysts.","Presentation covers the company's pipeline for Alzheimer's and psychiatric disorders.","No financial results, guidance, or specific clinical milestones were reported in the filing.","The update is a routine disclosure with no identified material changes to the company's strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-23-000871","json":"https://secwatch.observer/filing/0001214659-23-000871.json","markdown":"https://secwatch.observer/filing/0001214659-23-000871.md","text":"https://secwatch.observer/filing/0001214659-23-000871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923000871/0001214659-23-000871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923000871/r1192328k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T12:33:15.304554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}